Drug intelligence / Profile preview

SS-1 (China Medical University Hospital)

Development stage: Unknown
Lead developer: China Medical University Hospital
Administration: Oral

Overview

SS-1 is a traditional Chinese herbal formula developed by China Medical University Hospital for the treatment of Sjögren's syndrome, an autoimmune inflammatory disease. The formulation is a specific combination of three traditional decoctions: Gan-Lu-Yin, Sang-Ju-Yin, and Xuefu-Zhuyu-Decoction, mixed in a 2:1:1 ratio. SS-1 exerts anti-inflammatory, immunomodulatory, and antifibrotic effects. Clinical trial data indicates that the formula modulates immunity-related gene expression and exhibits anti-proliferative activity in B cells. In patients with Sjögren's syndrome, SS-1 has demonstrated significant improvements in tear production as measured by Schirmer's test.

Other names: SS1SS-1SS 1Chinese herbal formula SS-1

Beyond the preview

Go deeper on SS-1 (China Medical University Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SS-1 (China Medical University Hospital).

Explore the full profile